Apogee Therapeutics Inc (APGE)

08:15 AM

Apogee Therapeutics’ chief medical officer sells $139,801 in stock - Investing.com

08:15 AM

Apr 02, 2025

Teacher Retirement System of Texas Purchases 1,848 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Apr 02, 2025

Mar 29, 2025

Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Mar 29, 2025

Mar 29, 2025

Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17 - The AM Reporter

Mar 29, 2025

Mar 27, 2025

Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World

Mar 27, 2025

Mar 26, 2025

Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey

Mar 26, 2025

Mar 25, 2025

(APGE) Trading Advice - news.stocktradersdaily.com

Mar 25, 2025

Mar 22, 2025

Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Mar 22, 2025

Mar 22, 2025

12 Best IPO Stocks to Buy in 2025 - Insider Monkey

Mar 22, 2025

Mar 20, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 20, 2025

Mar 18, 2025

Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Mar 18, 2025

Mar 17, 2025

May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq

Mar 17, 2025

Mar 15, 2025

(APGE) Trading Signals - Stock Traders Daily

Mar 15, 2025

Mar 15, 2025

Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World

Mar 15, 2025

Mar 14, 2025

Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Mar 14, 2025

Mar 14, 2025

Apogee Therapeutics (NASDAQ:APGE) Trading Up 4.5%What's Next? - MarketBeat

Mar 14, 2025

Mar 13, 2025

Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Mar 13, 2025

Mar 13, 2025

Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Apogee Therapeutics initiated with a Buy at Citi - TipRanks

Mar 13, 2025

Mar 12, 2025

Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily

Mar 12, 2025

Mar 12, 2025

Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World

Mar 12, 2025

Mar 11, 2025

Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada

Mar 11, 2025

Mar 11, 2025

Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India

Mar 11, 2025

Mar 11, 2025

Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India

Mar 11, 2025

Mar 10, 2025

TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK

Mar 10, 2025

Mar 10, 2025

Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks

Mar 10, 2025

Mar 10, 2025

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL

Mar 10, 2025

Mar 08, 2025

Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa

Mar 08, 2025

Mar 07, 2025

Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock - Investing.com

Mar 07, 2025

Mar 07, 2025

Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa

Mar 07, 2025

Mar 07, 2025

Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com India

Mar 07, 2025

Mar 07, 2025

Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World

Mar 07, 2025

Mar 05, 2025

New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Mar 05, 2025

Mar 05, 2025

Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World

Mar 05, 2025

Mar 04, 2025

Where are the Opportunities in (APGE) - news.stocktradersdaily.com

Mar 04, 2025

Mar 04, 2025

Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks

Mar 04, 2025

Mar 04, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World

Mar 04, 2025

Mar 04, 2025

Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World

Mar 04, 2025

Mar 03, 2025

Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 03, 2025

Mar 03, 2025

APGEApogee Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Mar 03, 2025

Mar 03, 2025

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire

Mar 03, 2025

Mar 03, 2025

Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India

Mar 03, 2025

Mar 03, 2025

Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks

Mar 03, 2025

Mar 03, 2025

Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks

Mar 03, 2025

Mar 03, 2025

Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com

Mar 03, 2025